Related Experiment Video
Updated: Jun 8, 2026
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
Emerging natural killer cell immunotherapies: large-scale ex vivo production of highly potent anticancer effectors
Garnet Suck1, Mickey Boon Chai Koh
1Health Sciences Authority, Singapore. garnet_suck@hsa.gov.sg
Abstract:
Natural killer (NK) cell therapies are emerging worldwide as promising anticancer treatments, exploiting the fast cytolytic action of NK effectors and their potentially broad applicability against a wide range of malignancies. Until recently, clinical protocols have mainly involved freshly isolated NK cells or short- term activated NK cells or lymphokine-activated killer (LAK) cells. However, overall effector numbers and their anticancer potencies remained restricted, which poses a limiting factor to clinical efficacy. Recent developments in the field aim to improve clinical trial designs by increasing effector to target cell ratios in vivo and by application of superior cytotoxic NK effectors. Large-scale production of clinical grade NK cells through long-term activation in ex vivo cultures are another novel means in achieving these goals. However, such procedures require compliance with the strict Good Manufacturing Practice (GMP) regulations to ensure quality and safety of the NK cell product. Although the overall number of new protocols still remains comparably low, some of the protocols are already translated into clinical use. Also striking is the diversity of the different protocols proposed. We highlight in this review the most recent developments in the NK cell field with a focus on long-term NK cell expansion. Critical issues relating to this novel and promising type of therapy are highlighted and discussed.
Insights
Natural killer (NK) cell therapies offer a promising approach to cancer treatment. Long-term expansion of NK cells ex vivo is a novel strategy to enhance their anticancer potency and numbers for improved clinical efficacy.
Area of Science:
- Immunology
- Cell Therapy
- Oncology
Background:
- Natural killer (NK) cell therapies are emerging as potent anticancer treatments due to their cytolytic action against various malignancies.
- Current clinical protocols often use freshly isolated or short-term activated NK cells, limiting effector cell numbers and anticancer potency.
- Restricted effector numbers and potency represent a significant challenge to the clinical efficacy of NK cell-based cancer therapies.
Purpose of the Study:
- To review recent advancements in NK cell therapy, focusing on long-term NK cell expansion for enhanced anticancer efficacy.
- To discuss critical issues and challenges associated with large-scale, clinical-grade NK cell production under Good Manufacturing Practice (GMP) regulations.
- To highlight the diversity of proposed protocols and their translation into clinical use.
Main Methods:
- Review of recent developments in NK cell expansion techniques.
- Analysis of clinical trial designs aimed at increasing effector-to-target cell ratios and improving NK cell cytotoxicity.
- Discussion of Good Manufacturing Practice (GMP) compliance for large-scale production of clinical-grade NK cells.
Main Results:
- Long-term ex vivo expansion of NK cells offers a novel means to increase effector numbers and anticancer potency.
- Successful translation of some NK cell therapy protocols into clinical use, despite a relatively low number of new protocols.
- Diversity in proposed NK cell expansion protocols, indicating an evolving field.
Conclusions:
- Long-term expansion of NK cells ex vivo is a promising strategy to overcome limitations in current NK cell therapies.
- Ensuring quality and safety through GMP compliance is crucial for large-scale clinical-grade NK cell production.
- Continued research and development in NK cell expansion protocols are essential for advancing this novel anticancer therapy.
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy